Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03955471
Title Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer (MOONSTONE)
Recruitment Terminated
Gender female
Phase Phase II
Variant Requirements No
Sponsors Tesaro, Inc.
Indications

ovarian clear cell carcinoma

ovarian serous carcinoma

endometrioid ovary carcinoma

fallopian tube cancer

peritoneum cancer

Therapies

Dostarlimab-gxly + Niraparib

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
GSK Investigational Site Scottsdale Arizona 85258 United States Details
GSK Investigational Site Duarte California 91010 United States Details
GSK Investigational Site Newport Beach California 92663 United States Details
GSK Investigational Site Orange California 92868 United States Details
GSK Investigational Site Solvang California 93463 United States Details
GSK Investigational Site Deerfield Beach Florida 33442 United States Details
GSK Investigational Site Miami Florida 33136 United States Details
GSK Investigational Site Orlando Florida 32804 United States Details
GSK Investigational Site Tampa Florida 33612 United States Details
GSK Investigational Site Iowa City Iowa 52242-1009 United States Details
GSK Investigational Site Boston Massachusetts 02114 United States Details
GSK Investigational Site Boston Massachusetts 02215 United States Details
GSK Investigational Site Burlington Massachusetts 01805 United States Details
GSK Investigational Site Minneapolis Minnesota 55404 United States Details
GSK Investigational Site Jackson Mississippi 39216 United States Details
GSK Investigational Site New York New York 10022 United States Details
GSK Investigational Site Durham North Carolina 27710 United States Details
GSK Investigational Site Cleveland Ohio 44106 United States Details
GSK Investigational Site Cleveland Ohio 44124 United States Details
GSK Investigational Site Eugene Oregon 97401 United States Details
GSK Investigational Site Providence Rhode Island 02905 United States Details
GSK Investigational Site Chattanooga Tennessee 37403 United States Details
GSK Investigational Site Germantown Tennessee 38138 United States Details
GSK Investigational Site Austin Texas 78731 United States Details
GSK Investigational Site Fort Worth Texas 76104 United States Details
GSK Investigational Site San Antonio Texas 78229 United States Details
GSK Investigational Site Charlottesville Virginia 22903 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field